Navidea Biopharmaceuticals Announces Presentation of Results from Two Lymphoseek® and Radiolabeled Colloid Studies in Lymphatic

  Navidea Biopharmaceuticals Announces Presentation of Results from Two
  Lymphoseek® and Radiolabeled Colloid Studies in Lymphatic Mapping for Breast
  Cancer at SNMMI

    Single center clinical study and meta-analysis demonstrated ability of
         Lymphoseek to accurately identify tumor-draining lymph nodes

Business Wire

DUBLIN, Ohio -- June 10, 2013

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, today announced results
from two separate studies that compared the performance of Lymphoseek^®
(technetium Tc 99m tilmanocept) Injection, a novel receptor-targeted
small-molecule radiopharmaceutical recently approved by the U.S. Food and Drug
Administration, with that of radiolabeled sulfur colloid in breast cancer
patients undergoing diagnostic evaluation in lymphatic mapping procedures. The
studies were presented in oral presentations at the 2013 Annual Meeting of the
Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver,

Dr. Stephen Povoski, MD, of The Ohio State University, presented meta-analysis
results from Phase 3 clinical trials for Lymphoseek compared with published
data for radiolabeled colloid. A single center clinical research study was
presented by Dr. Jennifer Baker, MD, University of California San Diego, and
detailed that institution’s direct clinical experience with the two agents. Of
note, this abstract, "Tilmanocept identifies more positive nodes using fewer
sentinel lymph nodes compared to [99mTc] sulfur colloid in early stage breast
cancer patients,” received the “Dr. Tapan K. Chaudhuri, MD, FACNM, Award for
Best SNM Abstract Involving Breast Cancer Research,” awarded by the Education
and Research Foundation for Nuclear Medicine and Molecular Imaging. The award
was founded by Dr. Chaudhuri with a goal to promote research in breast cancer,
and was presented at the SNMMI Annual Meeting to recognize the best paper in
breast cancer research.

“We were pleased that these complementary studies of Lymphoseek in lymphatic
mapping procedures for patients with breast cancer could be shared at SNMMI,
because they highlight performance characteristics of this novel product that
are important to clinicians and the patients in their care,” said Mark Pykett,
V.M.D., Ph.D., CEO of Navidea Biopharmaceuticals. “Locating appropriate
tumor-draining lymph nodes, decreasing patient morbidity by removing as few
nodes as possible and scheduling procedures efficiently are key concerns for
physicians who conduct lymphatic mapping procedures, and we believe these data
further demonstrate the clinical benefit of Lymphoseek in addressing these
specific needs.”

“Results of our single institution study at UCSD in breast cancer demonstrate
the potential that receptor-targeted imaging agents may have in reliably
localizing tumor-draining lymph nodes, enhancing efficiencies, and in
optimizing patient management post-surgery,” said Anne Wallace, M.D., Chief,
Division of Plastic Surgery; Professor of Surgery, UC San Diego School of
Medicine; Director of the Breast Care Unit; UC San Diego Moores Cancer Center.
“Appropriate lymphatic mapping and lymph node biopsy can benefit certain
patients by sparing them removal of unnecessary lymphoid tissue and preventing
side effects such as lymphedema or swelling, pain and sensory changes,
scarring or disfigurement, and extended recovery times.”

Abstract Highlights:
"Tilmanocept identifies more positive nodes using fewer sentinel lymph nodes
compared to [99mTc] sulfur colloid in early stage breast cancer patients
(Baker et al, University California San Diego)

The independent, retrospective study conducted by UCSD compared the
performance of Lymphoseek and radiolabeled sulfur colloid in breast cancer
patients at a single institution. Results demonstrated statistically
significant results for Lymphoseek in the accurate identification of
tumor-draining lymph nodes. Lymphoseek detected 73% of tumor-positive nodes
whereas radiolabeled sulfur colloid detected 49%, and Lymphoseek demonstrated
a 98% early imaging success rate (the ability of the agent to be imaged in
less than 10 minutes). The late imaging failure rate (the ability of the agent
to be imaged within 2 hours) was 0% with Lymphoseek and 11.3% with
radiolabeled colloid.

Comparison of key sentinel node biopsy parameters for 99m Tc-tilmanocept
(TcTM) and 99mTc-sulfur colloid (TcSC) in breast cancer (Povoski et al, The
Ohio State University)
This meta-analysis analyzed the efficacy of Lymphoseek with that of
radiolabeled sulfur colloid by using data from Phase 3 clinical trials of
Lymphoseek in breast cancer in comparison to published data for radiolabeled
sulfur colloid. The study examined the endpoints of localization rate (the
percentage of patients with a “hot,” or radioactive, node found), and the
degree of localization (the number of “hot” nodes found per patient). The
localization rate for Lymphoseek was 99.9% (n=148), which was statistically
significant (p<0.001) against that for radiolabeled sulfur colloid with a
localization rate of 94%, (n=9,213). Lymphoseek located 2.08 nodes per
patient, as compared to 1.6 for radiolabeled sulfur colloid, which was
statistically significant (p<0.001)

Full abstracts from SNMMI can be found through the Annual Meeting website at

About Lymphoseek^®
Lymphoseek^® (technetium Tc 99m tilmanocept) Injection is a novel,
receptor-targeted, small-molecule radiopharmaceutical used in lymphatic
mapping procedures that are performed to help in the diagnostic evaluation of
potential cancer spread for patients with breast cancer and melanoma.
Lymphoseek is designed to identify the lymph nodes that drain from a primary
tumor, which have the highest probability of harboring cancer. Lymphoseek was
approved by the U.S. Food and Drug Administration in March, 2013 for use in
lymphatic mapping to assist in the localization of lymph nodes draining a
primary tumor in patients with breast cancer or melanoma. The Company
anticipates continuing development of Lymphoseek into other solid tumor areas
that may include head and neck cancers, prostate cancer, thyroid cancer,
lung/bronchus cancers, colorectal cancer and others.

Accurate diagnostic evaluation of cancer is critical, as it guides therapy
decisions and determines patient prognosis and risk of recurrence. According
to the American Cancer Society, approximately 232,000 new cases of breast
cancer, 77,000 new cases of melanoma and 67,000 new cases of head and
neck/oral cancer are expected to be diagnosed in the United States in 2013.

U.S. Indication and Important Safety Information About Lymphoseek
Lymphoseek (technetium Tc 99m tilmanocept) Injection is a lymphatic mapping
agent indicated for use with a hand-held gamma counter to assist in the
localization of lymph nodes draining a primary tumor site in patients with
breast cancer or melanoma.

Important Safety Information
In clinical trials with Lymphoseek, no serious hypersensitivity reactions were
reported, however Lymphoseek may pose a risk of such reactions due to its
chemical similarity to dextran. Serious hypersensitivity reactions have been
associated with dextran and modified forms of dextran (such as iron dextran

Prior to the administration of Lymphoseek, patients should be asked about
previous hypersensitivity reactions to drugs, in particular dextran and
modified forms of dextran. Resuscitation equipment and trained personnel
should be available at the time of Lymphoseek administration, and patients
observed for signs or symptoms of hypersensitivity following injection.

The most common adverse reactions are injection site irritation and/or pain


About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is actively developing
four radiopharmaceutical agent platforms – Lymphoseek^®, NAV4694, NAV5001 and
RIGScan^TM – to help identify the sites and pathways of undetected disease and
enable better diagnostic accuracy, clinical decision-making and, ultimately,
patient care. Navidea’s strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and advancing
the Company’s pipeline through selective acquisitions, global partnering and
commercialization efforts. For more information, please visit

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe
harbor for forward-looking statements made by or on behalf of the Company.
Statements in this news release, which relate to other than strictly
historical facts, such as statements about the Company’s plans and strategies,
expectations for future financial performance, new and existing products and
technologies, anticipated clinical and regulatory pathways, and markets for
the Company’s products are forward-looking statements within the meaning of
the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,”
and similar expressions identify forward-looking statements that speak only as
of the date hereof. Investors are cautioned that such statements involve risks
and uncertainties that could cause actual results to differ materially from
historical or anticipated results due to many factors including, but not
limited to, the Company’s continuing operating losses, uncertainty of market
acceptance of its products, reliance on third party manufacturers, accumulated
deficit, future capital needs, uncertainty of capital funding, dependence on
limited product line and distribution channels, competition, limited marketing
and manufacturing experience, risks of development of new products, regulatory
risks and other risks detailed in the Company’s most recent Annual Report on
Form 10-K and other Securities and Exchange Commission filings. The Company
undertakes no obligation to publicly update or revise any forward-looking


Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Executive VP & CFO
Stern Investor Relations, Inc.
Beth DelGiacco, 212-362-1200
Press spacebar to pause and continue. Press esc to stop.